{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:28:37Z","timestamp":1780464517264,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01276-0","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:38:26Z","timestamp":1738802306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions"],"prefix":"10.1007","volume":"27","author":[{"given":"Melody","family":"Hermel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hinkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikitha","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vashma","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"publisher","unstructured":"Bi Y, Li M, Liu Y, Li T, Lu J, Duan P et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med [Internet]. [cited 2024 Nov 24];0. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2412006","DOI":"10.1056\/NEJMoa2412006"},{"key":"1276_CR2","doi-asserted-by":"publisher","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG et al. Zerlasiran\u2014A small-interfering RNA targeting lipoprotein(a): A Phase 2 randomized clinical trial. JAMA [Internet]. 2024 [cited 2024 Nov 24]; Available from: https:\/\/doi.org\/10.1001\/jama.2024.21957","DOI":"10.1001\/jama.2024.21957"},{"key":"1276_CR3","doi-asserted-by":"publisher","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA [Internet]. 2024 [cited 2024 Nov 24]; Available from: https:\/\/doi.org\/10.1001\/jama.2024.24017","DOI":"10.1001\/jama.2024.24017"},{"key":"1276_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11883-023-01103-4","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Balachandran I, Foy J, Hermel M, Latif A, Krittanawong C, et al. Highlights of Cardiovascular Disease Prevention studies presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023;25:309\u201321.","journal-title":"Curr Atheroscler Rep"},{"key":"1276_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11883-024-01193-8","volume":"26","author":"M Hermel","year":"2024","unstructured":"Hermel M, Chiou A, Minhas AMK, Inam M, Waldman CE, Youngblood E, et al. Highlights of Cardiovascular Disease Prevention studies presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2024;26:119\u201331.","journal-title":"Curr Atheroscler Rep"},{"key":"1276_CR6","doi-asserted-by":"crossref","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42:e48\u201360.","DOI":"10.1161\/ATV.0000000000000147"},{"key":"1276_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in Context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"1276_CR8","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331\u20139.","journal-title":"JAMA"},{"key":"1276_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2022.07.009","volume":"356","author":"O Raitakari","year":"2022","unstructured":"Raitakari O, Kivel\u00e4 A, Pahkala K, Rovio S, Mykk\u00e4nen J, Ahola-Olli A, et al. Long-term tracking and population characteristics of lipoprotein (a) in the Cardiovascular Risk in Young finns Study. Atherosclerosis. 2022;356:18\u201327.","journal-title":"Atherosclerosis"},{"key":"1276_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pcad.2023.07.006","volume":"79","author":"C Krittanawong","year":"2023","unstructured":"Krittanawong C, Maitra NS, El-Sherbini AH, Shah N, Lavie CJ, Shapiro MD, et al. Lipoprotein(a) in clinical practice: a guide for the clinician. Prog Cardiovasc Dis. 2023;79:28\u201336.","journal-title":"Prog Cardiovasc Dis"},{"key":"1276_CR11","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43:3925\u201346.","journal-title":"Eur Heart J"},{"key":"1276_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.5551\/jat.ED265","volume":"31","author":"M Ogura","year":"2024","unstructured":"Ogura M, Obicetrapib. There is still life in the CETP inhibitor! J Atheroscler Thromb. 2024;31:1367\u20139.","journal-title":"J Atheroscler Thromb"},{"key":"1276_CR13","unstructured":"Obicetrapib on top. of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN - PubMed [Internet]. [cited 2025 Jan 3]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38705341\/"},{"key":"1276_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, et al. Efficacy and safety of Lerodalcibep in patients with or at high risk of Cardiovascular Disease: a Randomized Clinical Trial. JAMA Cardiol. 2024;9:800\u20137.","journal-title":"JAMA Cardiol"},{"key":"1276_CR15","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44:4272\u201380.","journal-title":"Eur Heart J"},{"key":"1276_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"1276_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1161\/CIRCULATIONAHA.107.701466","volume":"116","author":"JA Suaya","year":"2007","unstructured":"Suaya JA, Shepard DS, Normand S-LT, Ades PA, Prottas J, Stason WB. Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation. 2007;116:1653\u201362.","journal-title":"Circulation"},{"key":"1276_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"1276_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1001\/archinte.167.16.1720","volume":"167","author":"RP Bogers","year":"2007","unstructured":"Bogers RP, Bemelmans WJE, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167:1720\u20138.","journal-title":"Arch Intern Med"},{"key":"1276_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S0140-6736(13)61836-X","volume":"383","author":"Y Lu","year":"2014","unstructured":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1\u00b78 million participants. Lancet. 2014;383:970\u201383.","journal-title":"Lancet"},{"key":"1276_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24:15\u201330.","journal-title":"Cell Metab"},{"key":"1276_CR23","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"key":"1276_CR24","unstructured":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.| New England Journal of Medicine [Internet]. [cited 2024 Nov 30]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2409368?logout=true"},{"key":"1276_CR25","doi-asserted-by":"publisher","unstructured":"Temporal Effects of Plozasiran on Lipids and Lipoproteins in. Persistent Chylomicronemia [Internet]. [cited 2024 Nov 30]. Available from: https:\/\/www.ahajournals.org\/doi\/epdf\/https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072860","DOI":"10.1161\/CIRCULATIONAHA.124.072860"},{"key":"1276_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Collaboration, Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT), Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1276_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078\u201387.","journal-title":"N Engl J Med"},{"key":"1276_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071\u201380.","journal-title":"JAMA"},{"key":"1276_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","volume":"62","author":"AS Kini","year":"2013","unstructured":"Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1276_CR30","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jacc.2016.02.014","volume":"67","author":"S-J Park","year":"2016","unstructured":"Park S-J, Kang S-J, Ahn J-M, Chang M, Yun S-C, Roh JH, et al. Effect of Statin Treatment on modifying Plaque composition: a Double-Blind, randomized study. J Am Coll Cardiol. 2016;67:1772\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"1276_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jcmg.2011.11.012","volume":"5","author":"K Hattori","year":"2012","unstructured":"Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging. 2012;5:169\u201377.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1276_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.atherosclerosis.2008.05.014","volume":"202","author":"S Takarada","year":"2009","unstructured":"Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009;202:491\u20137.","journal-title":"Atherosclerosis"},{"key":"1276_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1276_CR34","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, et al. Effect of Evolocumab on Progression of Coronary Disease in statin-treated patients: the GLAGOV Randomized Clinical Trial. JAMA. 2016;316:2373\u201384.","journal-title":"JAMA"},{"key":"1276_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jacc.2016.10.029","volume":"69","author":"AS Kini","year":"2017","unstructured":"Kini AS, Vengrenyuk Y, Shameer K, Maehara A, Purushothaman M, Yoshimura T, et al. Intracoronary Imaging, Cholesterol Efflux, and transcriptomes after intensive statin treatment: the YELLOW II study. J Am Coll Cardiol. 2017;69:628\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"1276_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235\u20138.","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1007\/s11883-026-01411-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000}}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01276-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01276-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01276-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:30:16Z","timestamp":1776670216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01276-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01276-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to include the previously omitted sixth author, Carly Waldman.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11883-026-01411-5","URL":"https:\/\/doi.org\/10.1007\/s11883-026-01411-5","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"30"}}